Endothelin 2 (EDN2) (NM_001956) Human Tagged ORF Clone Lentiviral Particle
CAT#: RC206602L1V
- LentiORF®
-
Lenti ORF particles, EDN2 (Myc-DDK tagged) - Human endothelin 2 (EDN2), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 7,410.00
货期*
详询
规格
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (3)
Specifications
Product Data | |
Product Name | Endothelin 2 (EDN2) (NM_001956) Human Tagged ORF Clone Lentiviral Particle |
Synonyms | ET-2; ET2; PPET2 |
Vector | pLenti-C-Myc-DDK |
ACCN | NM_001956 |
ORF Size | 534 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(RC206602).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_001956.2 |
RefSeq Size | 1258 bp |
RefSeq ORF | 537 bp |
Locus ID | 1907 |
Protein Families | Druggable Genome, Secreted Protein |
MW | 20 kDa |
Gene Summary | This gene encodes a member of the endothelin protein family of secretory vasoconstrictive peptides. The preproprotein is processed to a short mature form which functions as a ligand for the endothelin receptors that initiate intracellular signaling events. This gene product is involved in a wide range of biological processes, such as hypertension and ovulation. Altered expression of this gene is implicated in tumorigenesis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2014] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
You may also need
其它Endothelin 2产品
Customer
Reviews
Loading...